Advertisement

The Urinary System

  • Chirukandath Gopinath
  • Vasanthi Mowat
Chapter

Abstract

Induced lesions affecting kidney and urinary bladder are included. In kidneys, changes affecting glomeruli, tubules, interstitium, and papilla are illustrated. These include degenerative, inflammatory, reparative, and proliferative changes. A few examples of induced tumours of kidney and urinary bladder are described.

Keywords

Distal Convoluted Tubule Cortical Tubule Outer Strip Renal Papillary Necrosis Chronic Nephropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Frazier KS, Seely JC, Hard GC, Betton G, Burnett R, Nakatsuji S, et al. Proliferative and nonproliferative lesions of the rat and mouse urinary system. Toxicol Pathol. 2012;40:14S–86.PubMedCrossRefGoogle Scholar
  2. 2.
    Ryan GB, Karnovsky MJ. An ultrastructural study of the mechanisms of proteinuria in aminonucleoside nephrosis. Kidney Int. 1975;8:219–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Weening JJ, Rennke HG. Glomerular permeability and polyanion in adriamycin nephrosis in the rat. Kidney Int. 1983;24:152–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Tucker MJ. Some effects of prolonged administration of a progestogen to dogs. Proc Eur Soc Study Drug Toxic. 1971;12:228–38.Google Scholar
  5. 5.
    Gopinath C, Prentice DE, Lewis DJ. The urinary system. In: Atlas of experimental toxicological pathology. Lancaster: MTP Press Ltd; 1987. p. 77.CrossRefGoogle Scholar
  6. 6.
    Mazue G, Newman AJ, Scampini G, Della TP, Hard GC, Iatropoulos MJ, et al. The histopathology of kidney changes in rats and monkeys following intravenous administration of massive doses of FCE 26184, human basic fibroblast growth factor. Toxicol Pathol. 1993;21:490–501.PubMedCrossRefGoogle Scholar
  7. 7.
    Robinson CJ, Egoron I, Balazs T. Strain differences in the induction of antinuclear antibodies by mercuric chloride, gold sodium thiomaleate and D-penicillamine in inbred mice. Fed Proc. 1983;42:1213.Google Scholar
  8. 8.
    Robinson CJ, Abraham AA, Balazs T. Induction of anti-nuclear antibodies by mercuric chloride in mice. Clin Exp Immunol. 1984;58:300–6.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Wright NG, Nash AS. Experimental ampicillin glomerulonephropath. J Comp Pathol. 1984;94:357–61.PubMedCrossRefGoogle Scholar
  10. 10.
    Crabtree C. The structure of Bowman’s capsule and castrate and testosterone treated mice as an index of hormonal effect on the renal cortex. Endocrinology. 1941;29:197–203.CrossRefGoogle Scholar
  11. 11.
    Greaves P. Urinary tract. In: Histopathology of preclinical toxicity studies. Amsterdam: Academic; 2007. p. 570.CrossRefGoogle Scholar
  12. 12.
    Hard GC, Seely JC. Recommendations for the interpretation of renal tubule proliferative lesions occurring in rat kidneys with advanced chronic progressive nephropathy (CPN). Toxicol Pathol. 2005;33:641–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Hard GC, Seely JC. Histological investigation of diagnostically challenging tubule profiles in advanced chronic progressive nephropathy (CPN) in the Fischer 344 rat. Toxicol Pathol. 2006;34:941–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Hard GC, Betz LJ, Seely JC. Association of advanced chronic progressive nephropathy (CPN) with renal tubule tumors and precursor hyperplasia in control F344 rats from two-year carcinogenicity studies. Toxicol Pathol. 2012;40:473–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Travlos GS, Hard GC, Betz LJ, Kissling GE. Chronic progressive nephropathy in male F344 rats in 90-day toxicity studies: its occurrence and association with renal tubule tumors in subsequent 2-year bioassays. Toxicol Pathol. 2011;39:381–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Hard GC, Whysner J, English JC, Zang E, Williams GM. Relationship of hydroquinone-associated rat renal tumors with spontaneous chronic progressive nephropathy. Toxicol Pathol. 1997;25:132–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Hard GC, Banton MI, Bretzlaff RS, Dekant W, Fowles JR, Mallett AK, et al. Consideration of rat chronic progressive nephropathy in regulatory evaluations for carcinogenicity. Toxicol Sci. 2013;132:268–75.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Hard GC, Khan KN. A contemporary overview of chronic progressive nephropathy in the laboratory rat, and its significance for human risk assessment. Toxicol Pathol. 2004;32:171–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Wold JS. Cephalosporin toxicity. In: Hook JB, editor. Toxicology of the kidney. New York: Raven; 1981. p. 251–66.Google Scholar
  20. 20.
    Bulger RE. Renal damage caused by heavy metals. Toxicol Pathol. 1986;14:58–65.PubMedCrossRefGoogle Scholar
  21. 21.
    Hottendorf GH, Williams PD. Aminoglycoside nephrotoxicity. Toxicol Pathol. 1986;14:66–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Mihatsch MJ, Ryffel B, Hermle M, Brunner FP, Thiel G. Morphology of cyclosporine nephrotoxicity in the rat. Clin Nephrol. 1986;25 Suppl 1:S2–8.PubMedGoogle Scholar
  23. 23.
    Phillips RD, Cockrell BY. Kidney structural changes in rats following inhalation exposure to C10-C11 isoparaffinic solvent. Toxicology. 1984;33:261–73.PubMedCrossRefGoogle Scholar
  24. 24.
    Hard GC. Some aids to histological recognition of hyaline droplet nephropathy in ninety-day toxicity studies. Toxicol Pathol. 2008;36:1014–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Alden CL. A review of unique male rat hydrocarbon nephropathy. Toxicol Pathol. 1986;14:109–11.PubMedCrossRefGoogle Scholar
  26. 26.
    Tucker Jr WE, Macklin AW, Szot RJ, Johnston RE, Elion GB, de Miranda P, et al. Preclinical toxicology studies with acyclovir: acute and subchronic tests. Fundam Appl Toxicol. 1983;3:573–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Bach PH, Bridges JW. Chemically induced renal papillary necrosis and upper urothelial carcinoma. Part 1. Crit Rev Toxicol. 1985;15:217–329.PubMedCrossRefGoogle Scholar
  28. 28.
    Bach PH, Bridges JW. Chemically induced renal papillary necrosis and upper urothelial carcinoma. Part 2. CRC Crit Rev Toxicol. 1985;15:331–441.PubMedCrossRefGoogle Scholar
  29. 29.
    Owen RA, Durand-Cavagna G, Molon-Noblot S, Boussiquet-Leroux C, Berry PH, Tonkonoh N, et al. Renal papillary cytoplasmic granularity and potassium depletion induced by carbonic anhydrase inhibitors in rats. Toxicol Pathol. 1993;21:449–55.PubMedCrossRefGoogle Scholar
  30. 30.
    Owen RA, Molon-Noblot S, Hubert MF, Siegl PK, Eydelloth RS, Keenan KP. Juxtaglomerular cell hypertrophy and hyperplasia induced in rhesus monkeys by angiotensin II receptor antagonists. Lab Invest. 1994;71:543–51.PubMedGoogle Scholar
  31. 31.
    Owen RA, Molon-Noblot S, Hubert MF, Kindt MV, Keenan KP, Eydelloth RS. The morphology of juxtaglomerular cell hyperplasia and hypertrophy in normotensive rats and monkeys given an angiotensin II receptor antagonist. Toxicol Pathol. 1994;22:606–19.PubMedCrossRefGoogle Scholar
  32. 32.
    Hard GC. Mechanisms of chemically induced renal carcinogenesis in the laboratory rodent. Toxicol Pathol. 1998;26:104–12.PubMedCrossRefGoogle Scholar
  33. 33.
    Hard GC, Seely JC, Kissling GE, Betz LJ. Spontaneous occurrence of a distinctive renal tubule tumor phenotype in rat carcinogenicity studies conducted by the national toxicology program. Toxicol Pathol. 2008;36:388–96.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Hall WC, Elder B, Walker CL, Cai SL, Peters DG, Goodman DG, et al. Spontaneous renal tubular hyperplastic and neoplastic lesions in three Sprague–Dawley rats from a 90-day toxicity study. Toxicol Pathol. 2007;35:233–41.PubMedCrossRefGoogle Scholar
  35. 35.
    Driver HE, White IN, Butler WH. Dose–response relationships in chemical carcinogenesis: renal mesenchymal tumours induced in the rat by single dose dimethylnitrosamine. Br J Exp Pathol. 1987;68:133–43.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Hard GC. Experimental models for the sequential analysis of chemically-induced renal carcinogenesis. Toxicol Pathol. 1986;14:112–22.PubMedCrossRefGoogle Scholar
  37. 37.
    Hara H, Miyao M, Moriki T, Kutsukake F, Yamane T. Histological and ultrastructural studies of nephroblastoma in rats induced transplacentally by ethylnitrosourea. Acta Pathol Jpn. 1982;32:385–98.PubMedGoogle Scholar
  38. 38.
    Johansson SL. Carcinogenicity of analgesics: long-term treatment of Sprague–Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetaminophen). Int J Cancer. 1981;27:521–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Wisler JA, Afshari C, Fielden M, Zimmermann C, Taylor S, Carnahan J, et al. Raf inhibition causes extensive multiple tissue hyperplasia and urinary bladder neoplasia in the rat. Toxicol Pathol. 2011;39:809–22.PubMedCrossRefGoogle Scholar
  40. 40.
    El Hage H. Preclinical and clinical safety assessments for PPAR agonists. Rockville: Center for Drug Evaluation and Research, FDA; 2004.Google Scholar
  41. 41.
    Yki-Yarvinen H. Drug therapy, thiazolidinediones. N Engl J Med. 2004;351:1106–18.CrossRefGoogle Scholar
  42. 42.
    Hardisty JF, Anderson DC, Brodie S, Cline JM, Hahn FF, Kolenda-Roberts H, et al. Histopathology of the urinary bladders of cynomolgus monkeys treated with PPAR agonists. Toxicol Pathol. 2008;36:769–76.PubMedCrossRefGoogle Scholar
  43. 43.
    Molon-Noblot S, Boussiquet-Leroux C, Owen RA, Irisarri E, Durand-Cavagna G, Peter CP, et al. Rat urinary bladder hyperplasia induced by oral administration of carbonic anhydrase inhibitors. Toxicol Pathol. 1992;20:93–102.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Chirukandath Gopinath
    • 1
  • Vasanthi Mowat
    • 2
  1. 1.Consultant in Toxicology and PathologyCambridgeshireUK
  2. 2.Huntingdon Life SciencesCambridgeshireUK

Personalised recommendations